Pioneering Progress and Partnership in SCLC: Insights for Modern Multidisciplinary Clinicians

https://www.medscape.org/advances/pioneering-progress-and-partnership-sclc-insights-modern-2025a1000y7k

IMPACT EBC: IMPlementing Advances in Cancer Treatment for Patients With HR+/HER2- Early Breast Cancer Moving Patient Care Forward

https://www.medscape.org/sites/advances/early-breast-cancer

HR-Positive Breast Cancer

The approval of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) has permanently changed the treatment paradigm of this disease. Clinicians are faced with increasingly complex decision-making and must be educated on the optimal use of these agents in clinical practice. This Clinical Advances educational initiative will assist clinicians in making more informed choices for their patients by discussing recent data and real-world experiences on the efficacy and safety of CDK4/6 inhibitors in different settings and different patient subtypes. https://www.medscape.org/sites/advances/metastatic-breast-cancer

Oncology: Focus on the Changing Therapeutic Landscape

https://www.medscape.org/sites/advances/novel-treatments-oncology

Innovations in Women's Health Coalition

https://www.medscape.org/sites/advances/iwhc

The Gynecologic Oncology Clinic: Real-Time Case Review of Patients With Endometrial or Ovarian Cancer Authors: Pamela T. Soliman, MD, MPH; Floor J. Backes, MD; Richard T. Penson, MD, MRCP

https://www.medscape.org/viewarticle/gynecologic-oncology-clinic-real-time-case-review-patients-2025a1000h2s?page=1

Who Benefited From UK Drug Decisions in 2025? Dr Rob Hicks

https://www.medscape.com/viewarticle/who-benefited-uk-drug-decisions-2025-2025a10010d7